Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas

International Journal of Cancer. Journal International Du Cancer
Elodie ManiéMarc-Henri Stern

Abstract

Therapeutic strategies targeting Homologous Recombination Deficiency (HRD) in breast cancer requires patient stratification. The LST (Large-scale State Transitions) genomic signature previously validated for triple-negative breast carcinomas (TNBC) was evaluated as biomarker of HRD in luminal (hormone receptor positive) and HER2-overexpressing (HER2+) tumors. The LST genomic signature related to the number of large-scale chromosomal breakpoints in SNP-array tumor profile was applied to identify HRD in in-house and TCGA sets of breast tumors, in which the status of BRCA1/2 and other genes was also investigated. In the in-house dataset, HRD was predicted in 5% (20/385) of sporadic tumors luminal or HER2+ by the LST genomic signature and the inactivation of BRCA1, BRCA2 or RAD51C confirmed this prediction in 75% (12/16) of the tested cases. In 14% (6/43) of tumors occurring in BRCA1/2 mutant carriers, the corresponding wild-type allele was retained emphasizing the importance of determining the tumor status. In the TCGA luminal and HER2+ subtypes HRD incidence was estimated at 5% (18/329, 95%CI: 5-8%) and 2% (1/59, 95%CI: 2-9%), respectively. In TNBC cisplatin-based neo-adjuvant clinical trials, HRD is shown to be a necessary condi...Continue Reading

References

Apr 6, 2000·Journal of the National Cancer Institute·M EstellerJ G Herman
Nov 16, 2004·Genes, Chromosomes & Cancer·José PalaciosJavier Benítez
Nov 24, 2004·Journal of Mammary Gland Biology and Neoplasia·Deborah Thompson, Douglas Easton
Oct 4, 2006·Oncogene·N C TurnerA N Tutt
Apr 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sining Chen, Giovanni Parmigiani
Feb 24, 2010·Nature Reviews. Molecular Cell Biology·Mary Ellen Moynahan, Maria Jasin
Apr 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter C FongStan B Kaye
Jul 8, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bryan T J HennessyGordon B Mills
Aug 10, 2010·Annual Review of Genetics·Wolf-Dietrich HeyerJie Liu
Mar 3, 2011·Genes & Development·Sophie E Polo, Stephen P Jackson
Jul 2, 2011·Nature·UNKNOWN Cancer Genome Atlas Research Network
Dec 24, 2011·Nature Reviews. Cancer·Rohini RoySimon N Powell
Jan 25, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicolas ServantMarc J van de Vijver
May 12, 2012·Cancer Discovery·Nicolai J BirkbakAndrea L Richardson
Aug 25, 2012·Nature Reviews. Cancer·Peter Bouwman, Jos Jonkers
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
May 1, 2013·Journal of the National Cancer Institute·Nasim MavaddatUNKNOWN EMBRACE
May 21, 2013·American Journal of Human Genetics·Tatiana PopovaMarc-Henri Stern
Jun 12, 2013·International Journal of Cancer. Journal International Du Cancer·Nicolas PécuchetMarc-Henri Stern
Aug 15, 2013·European Journal of Human Genetics : EJHG·Julien TarabeuxClaude Houdayer
Oct 22, 2013·BMC Cancer·Lisa GolmardDominique Stoppa-Lyonnet
Nov 19, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kathryn P PenningtonElizabeth M Swisher
Jun 26, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kishan A T NaipalDik C van Gent
Aug 6, 2014·Breast Cancer Research : BCR·Johnathan A WatkinsAndrew N J Tutt
Aug 8, 2014·The New England Journal of Medicine·Antonis C AntoniouMarc Tischkowitz
Aug 21, 2014·European Journal of Human Genetics : EJHG·Alexandra J van den BroekMarjanka K Schmidt
Oct 23, 2014·The New England Journal of Medicine·Antonis C AntoniouMarc Tischkowitz
Mar 18, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Clare L ScottScott H Kaufmann
Apr 8, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven J IsakoffLeif W Ellisen
May 28, 2015·The New England Journal of Medicine·Douglas F EastonWilliam D Foulkes

❮ Previous
Next ❯

Citations

Oct 22, 2016·Cancer Letters·Gaëlle JudesDominique Bernard-Gallon
Jul 19, 2020·Journal of Clinical Medicine·Ludivine DionVincent Lavoué
Oct 9, 2019·Proceedings of the National Academy of Sciences of the United States of America·Jonathan E LeemanDaniel S Higginson
Apr 19, 2018·Breast Cancer Research : BCR·Anne-Laure RenaultFabienne Lesueur
May 2, 2018·Scientific Reports·Francesco IorioJulio Saez-Rodriguez
May 5, 2018·Briefings in Bioinformatics·L Cristobal Monraz GomezInna Kuperstein
Apr 8, 2020·Frontiers in Genetics·Yann KiefferFatima Mechta-Grigoriou
May 23, 2018·Journal of the National Cancer Institute·Michal M HoppeAnand D Jeyasekharan
Dec 3, 2016·Molecular Cancer Therapeutics·Maike ZimmermannPaul T Henderson
Jul 26, 2019·The Breast : Official Journal of the European Society of Mastology·Shani Paluch-Shimon, Ella Evron
Mar 19, 2021·The Pharmacogenomics Journal·Manar S ShafatJohnathan Watkins
Apr 14, 2017·Journal of Gynecology Obstetrics and Human Reproduction·V LavouéT de la Motte Rouge

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.